Latest Macroeconomics News

State Gas Limited advances its Rolleston West Project with successful drilling of two vertical wells confirming coal and gas continuity, aiming to establish a maiden 2P reserve. Concurrently, the company expands its high density natural gas supply, targeting significant revenue growth through a six-truck dual fuel trial.

OM Holdings Limited has reported Q1 2025 production in line with guidance, completed a significant refinancing, and highlighted ongoing operational trials amid evolving market conditions for ferrosilicon and manganese.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Atomos Limited reported a $2.3 million operating cash outflow in Q3 FY25 amid seasonal softness and tariff challenges, while announcing a leadership change and a bold expansion into new product categories beyond its core monitor-recorder business.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Galan Lithium has locked in a binding funding and offtake agreement with Authium Limited for its Hombre Muerto West project, significantly reducing capital and operating costs. The company raised approximately A$13 million via placement and plans further shareholder funding, aiming for lithium chloride production in H1 2026.

BirdDog Technology reported a slight 4.1% decline in Q3 FY25 sales to A$3.6 million while progressing strongly on its next-generation product roadmap and implementing significant cost reductions.

Plenti Group Limited reported a standout 4Q25 with record loan originations of $407 million and a 126% jump in full-year Cash NPAT to $13.8 million, driven by robust growth across automotive, renewable energy, and personal lending.

Pureprofile Limited reported a robust 16% revenue increase in Q3 FY25, driven by strong international expansion and new AI-powered solutions, while reaffirming its FY25 financial guidance.

Pureprofile Limited has reported a robust Q3 FY25 with revenue up 16% and EBITDA up 16% year-on-year, driving a 20% increase in year-to-date revenue and a 35% jump in EBITDA. The company’s international expansion and new AI-driven solutions underpin its confident outlook for FY25.

Visionflex Group reported a 46% year-on-year rise in annual recurring revenue to $1.7 million, secured key contracts including a $1 million virtual nursing pilot, and targets operating cash flow positivity in Q4 FY25.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.